Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complement these approaches. We present methods for developing...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-12-01
|
| Series: | Cell Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124717317035 |
| _version_ | 1818260514473508864 |
|---|---|
| author | David P. Kodack Anna F. Farago Anahita Dastur Matthew A. Held Leila Dardaei Luc Friboulet Friedrich von Flotow Leah J. Damon Dana Lee Melissa Parks Richard Dicecca Max Greenberg Krystina E. Kattermann Amanda K. Riley Florian J. Fintelmann Coleen Rizzo Zofia Piotrowska Alice T. Shaw Justin F. Gainor Lecia V. Sequist Matthew J. Niederst Jeffrey A. Engelman Cyril H. Benes |
| author_facet | David P. Kodack Anna F. Farago Anahita Dastur Matthew A. Held Leila Dardaei Luc Friboulet Friedrich von Flotow Leah J. Damon Dana Lee Melissa Parks Richard Dicecca Max Greenberg Krystina E. Kattermann Amanda K. Riley Florian J. Fintelmann Coleen Rizzo Zofia Piotrowska Alice T. Shaw Justin F. Gainor Lecia V. Sequist Matthew J. Niederst Jeffrey A. Engelman Cyril H. Benes |
| author_sort | David P. Kodack |
| collection | DOAJ |
| description | Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care. |
| first_indexed | 2024-12-12T18:32:33Z |
| format | Article |
| id | doaj.art-016db17b42214179a6109aad4764e0a1 |
| institution | Directory Open Access Journal |
| issn | 2211-1247 |
| language | English |
| last_indexed | 2024-12-12T18:32:33Z |
| publishDate | 2017-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Reports |
| spelling | doaj.art-016db17b42214179a6109aad4764e0a12022-12-22T00:15:52ZengElsevierCell Reports2211-12472017-12-0121113298330910.1016/j.celrep.2017.11.051Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P. Kodack0Anna F. Farago1Anahita Dastur2Matthew A. Held3Leila Dardaei4Luc Friboulet5Friedrich von Flotow6Leah J. Damon7Dana Lee8Melissa Parks9Richard Dicecca10Max Greenberg11Krystina E. Kattermann12Amanda K. Riley13Florian J. Fintelmann14Coleen Rizzo15Zofia Piotrowska16Alice T. Shaw17Justin F. Gainor18Lecia V. Sequist19Matthew J. Niederst20Jeffrey A. Engelman21Cyril H. Benes22Massachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAMassachusetts General Hospital Cancer Center, Boston, MA 02129, USAPersonalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care.http://www.sciencedirect.com/science/article/pii/S2211124717317035patient-derived cancer cellsNSCLCpersonalized medicine |
| spellingShingle | David P. Kodack Anna F. Farago Anahita Dastur Matthew A. Held Leila Dardaei Luc Friboulet Friedrich von Flotow Leah J. Damon Dana Lee Melissa Parks Richard Dicecca Max Greenberg Krystina E. Kattermann Amanda K. Riley Florian J. Fintelmann Coleen Rizzo Zofia Piotrowska Alice T. Shaw Justin F. Gainor Lecia V. Sequist Matthew J. Niederst Jeffrey A. Engelman Cyril H. Benes Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care Cell Reports patient-derived cancer cells NSCLC personalized medicine |
| title | Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care |
| title_full | Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care |
| title_fullStr | Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care |
| title_full_unstemmed | Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care |
| title_short | Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care |
| title_sort | primary patient derived cancer cells and their potential for personalized cancer patient care |
| topic | patient-derived cancer cells NSCLC personalized medicine |
| url | http://www.sciencedirect.com/science/article/pii/S2211124717317035 |
| work_keys_str_mv | AT davidpkodack primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT annaffarago primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT anahitadastur primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT matthewaheld primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT leiladardaei primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT lucfriboulet primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT friedrichvonflotow primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT leahjdamon primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT danalee primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT melissaparks primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT richarddicecca primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT maxgreenberg primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT krystinaekattermann primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT amandakriley primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT florianjfintelmann primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT coleenrizzo primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT zofiapiotrowska primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT alicetshaw primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT justinfgainor primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT leciavsequist primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT matthewjniederst primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT jeffreyaengelman primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare AT cyrilhbenes primarypatientderivedcancercellsandtheirpotentialforpersonalizedcancerpatientcare |